These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33674869)

  • 1. Targeted Antibiotics for Trachoma: A Cluster-Randomized Trial.
    Melo JS; Aragie S; Chernet A; Tadesse Z; Dagnew A; Hailu D; Haile M; Zeru T; Wittberg DM; Nash SD; Callahan EK; Arnold BF; Porco TC; Lietman TM; Keenan JD
    Clin Infect Dis; 2021 Sep; 73(6):979-986. PubMed ID: 33674869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).
    Mahmud H; Haile BA; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Liu Z; Callahan EK; Cotter SY; Varnado NE; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Clin Infect Dis; 2023 Aug; 77(3):388-395. PubMed ID: 37021692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When the Neighboring Village is Not Treated: Role of Geographic Proximity to Communities Not Receiving Mass Antibiotics for Trachoma.
    Mosenia A; Haile BA; Shiferaw A; Gebresillasie S; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Callahan EK; Zhou Z; Lietman TM; Keenan JD
    Clin Infect Dis; 2023 Mar; 76(6):1038-1042. PubMed ID: 36477547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial.
    Arzika AM; Mindo-Panusis D; Abdou A; Kadri B; Nassirou B; Maliki R; Alsoudi AF; Zhang T; Cotter SY; Lebas E; O'Brien KS; Callahan EK; Bailey RL; West SK; Goodhew EB; Martin DL; Arnold BF; Porco TC; Lietman TM; Keenan JD;
    JAMA Netw Open; 2022 Aug; 5(8):e2228244. PubMed ID: 35997979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
    Lietman TM; Ayele B; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Nash SD; Porco TC; Keenan JD; Oldenburg CE
    Am J Ophthalmol; 2020 Jun; 214():143-150. PubMed ID: 32171768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.
    Oldenburg CE; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Gaynor BD; Keenan JD; Lietman TM
    Am J Trop Med Hyg; 2018 Feb; 98(2):389-395. PubMed ID: 29260659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA): a two-arm, parallel-group, cluster-randomised trial.
    Aragie S; Wittberg DM; Tadesse W; Dagnew A; Hailu D; Chernet A; Melo JS; Aiemjoy K; Haile M; Zeru T; Tadesse Z; Gwyn S; Martin DL; Arnold BF; Freeman MC; Nash SD; Callahan EK; Porco TC; Lietman TM; Keenan JD
    Lancet Glob Health; 2022 Jan; 10(1):e87-e95. PubMed ID: 34919861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
    JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Gaynor BD; Keenan JD; Lietman TM; Oldenburg CE
    Br J Ophthalmol; 2018 May; 102(5):680-686. PubMed ID: 28893761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.
    Amza A; Kadri B; Nassirou B; Stoller NE; Yu SN; Zhou Z; Chin S; West SK; Bailey RL; Mabey DC; Keenan JD; Porco TC; Lietman TM; Gaynor BD;
    PLoS Negl Trop Dis; 2012; 6(4):e1586. PubMed ID: 22545165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; Zhou Z; Bailey RL; Mabey DC; Porco TC; Keenan JD; Gaynor BD; West SK; Lietman TM
    Clin Infect Dis; 2017 Mar; 64(6):743-750. PubMed ID: 27956455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics for trachoma.
    Evans JR; Solomon AW
    Cochrane Database Syst Rev; 2011 Mar; (3):CD001860. PubMed ID: 21412875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.